DCGI nod awaited for Oxford University-Astrazeneca’s vaccine

Serum Institute of India (SII) is partnering with AstraZeneca to manufacture Covishield.

102
Medicine Injection Vaccine
Picture: Pixabay

Last Updated on January 2, 2021 by The Health Master

CDSCO’s Subject Expert Committee (SEC) on C-19 has endorsed emergency use authorisation (EUA) for Oxford University-Astrazeneca’s C-19 vaccine candidate ‘Covishield’, as per reports.

It is the first vaccine candidate to get a recommendation from the expert panel for EUA in India. The approval from Drug Controller General of India (DCGI) is awaited.

Serum Institute of India (SII) is partnering with AstraZeneca to manufacture Covishield.

The SEC had earlier sought additional safety and immunogenicity data from SII and met today to review the matter. SII had applied to the DCGI for EUA for Covishield on December 6, 2020.


Also read | AstraZeneca vaccine may be first to get approval in India: Sources


The SEC is also looking at the EUA applications of Pfizer and Bharat Biotech. It has started reviewing the EUA application for Bharat Biotech’s Covaxin, but a final decision has not been taken yet, as per reports.

Earlier, VG Somani, Drug Controller General of India had hinted that India may grant EUA for a C-19 vaccine in the New Year.


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here